Compare Lionsgate Studios Corp Common Shares (LION) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lionsgate Studios Corp Common Shares vs McKesson Corporation — how do they compare? Lionsgate Studios Corp Common Shares trades at $10.86 (market cap $3.31B), while McKesson Corporation trades at $983.95 (market cap $112.15B). The key difference: McKesson Corporation is far larger — about 33.9× Lionsgate Studios Corp Common Shares's market cap, and McKesson Corporation pays a 0.39% dividend while Lionsgate Studios Corp Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lionsgate Studios Corp Common Shares for 0 Days and McKesson Corporation for 74 Days on average.
| LION | MCK | |
|---|---|---|
Market Cap | $3.31B | $112.15B |
Volume | 2,146,134 | 743,618 |
Sector | Technology | Health |
52-Week High | $16.40 | $995.69 |
52-Week Low | $5.91 | $725.17 |
Typical Hold Time | 0 Days | 74 Days |
Enterprise Value | $6.82B | $118.68B |
Dividend Yield | — | 0.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LION trades at $11.12, up 0.36% on the day, with a market cap of approximately $1.3 billion. The stock shows mixed signals: strong analyst support (87.5% buy rating) and a consensus price target of $16.80 suggest upside, but negative net income and shareholder equity highlight financial strain. Recent Q1 2027 earnings beat estimates with EPS of $0.37, yet the company remains unprofitable with a net loss of $128.5 million in 2025. Takeover interest from firms like Bolloré adds speculative appeal.
The outlook hinges on operational turnaround and potential M&A. Revenue growth from hit films like 'Michael' and a valuable content library offer catalysts, but high debt ($3.65B total) and consistent losses pose significant risks. Investors should weigh the 51% upside to price targets against fundamental weaknesses and industry volatility.
McKesson Corporation (MCK) trades at $976.57, up 2.18% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with three consecutive quarterly beats and revenue growth from $309B to $359B annually. Recent news highlights the CVS Health partnership extension through 2032, reinforcing distribution stability. Technical indicators show bullish moving averages but overbought RSI levels near resistance at $978.
Outlook remains positive given earnings momentum and strategic partnerships, though valuation at 25.8x P/E and thin 1.12% net margins pose risks. Analysts maintain 80.65% buy ratings with $956 consensus target, slightly below current price. Key risks include drug pricing pressure and macroeconomic sensitivity. Institutional accumulation supports medium-term upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lionsgate Studios Corp Common Shares
Lionsgate Studios Corp. is a standalone content company that develops, finances, produces, and distributes motion pictures and television series, licensing its content to theaters, streaming platforms, television networks, and home entertainment channels.
Read more on LION →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
